Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice

JCI Insight
|June 17, 2020
PubMed

Insights

Aging impairs tissue repair due to oxidative stress. Targeting bromodomain-containing protein 4 (Brd4) with BET inhibitors reverses age-related lung fibrosis by regulating NADPH oxidase 4 (Nox4).

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Aging Research

Background:

  • Tissue regeneration declines with age, linked to increased oxidative stress.
  • NADPH oxidase 4 (Nox4) expression is elevated in aged mice with poor fibrosis resolution.
  • Bromodomain-containing protein 4 (Brd4) is an epigenetic reader involved in gene regulation.

Purpose of the Study:

  • To investigate the role of Brd4 and p300 in regulating Nox4 expression.
  • To evaluate the efficacy of BET inhibitors in reversing age-associated lung fibrosis in vivo.

Main Methods:

  • Examined the interaction of Brd4, p300, and acetylated histone H4K16 at the Nox4 promoter.
  • Utilized BET inhibitors (I-BET-762, JQ1, OTX015) to downregulate Nox4.
  • Treated aged mice with established lung fibrosis using OTX015.

Main Results:

  • BET inhibition disrupted the association of Brd4, p300, and acetylated histone H4K16 with the Nox4 promoter.
  • BET inhibitors effectively downregulated Nox4 gene expression and activity.
  • OTX015 treatment restored fibrosis resolution capacity in aged mice.

Conclusions:

  • Epigenetic regulation of Nox4 by Brd4 and p300 is implicated in age-related lung fibrosis.
  • BET/Brd4 inhibition presents a promising therapeutic strategy for age-related fibrotic lung diseases.